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KRAS is the most frequently mutated oncogene in
human cancer, yet no therapies are available to treat
KRAS mutant cancers. We used two independent
reverse genetic approaches to identify components
of the RAS-signaling pathways required for growth
of KRAS mutant tumors. Small interfering RNA
(siRNA) screening of 37KRASmutant colorectal can-
cer cell lines showed that RAF1 suppression was
synthetic lethal with MEK inhibition. An unbiased
kinome short hairpin RNA (shRNA)-based screen
confirmed this synthetic lethal interaction in colo-
rectal as well as in lung cancer cells bearing KRAS
mutations. Compounds targeting RAF kinases can
reverse resistance to the MEK inhibitor selumetinib.
MEK inhibition induces RAS activation and BRAF-
RAF1 dimerization and sustains MEK-ERK signaling,
which is responsible for intrinsic resistance to selu-
metinib. Prolonged dual blockade of RAF and MEK
leads to persistent ERK suppression and efficiently
induces apoptosis. Our data underlie the relevance
of developing combinatorial regimens of drugs
targeting the RAF-MEK pathway in KRAS mutant
tumors.INTRODUCTION
Mutations in the gene encoding the guanosine triphosphatase
protein KRAS, the principal of the three isoforms of RAS, are
present in approximately 20% of all cancers and are associ-
ated with poor prognosis and resistance to therapy (Prior
et al., 2012; Pylayeva-Gupta et al., 2011). Oncogenic mutations
occur most frequently in codons 12, 13, 61, and 146, and the
resulting proteins are resistant to GAP-mediated guanosine
triphosphate (GTP) hydrolysis, rendering them constitutivelyCell Reactive (Cox and Der, 2010; Pylayeva-Gupta et al., 2011). Efforts
to pharmacologically target KRAS directly have been so far
unsuccessful. Innovative approaches recently challenged this
assumption; nevertheless, development of clinical KRAS inhib-
itors is not yet within reach (Ostrem et al., 2013; Zimmermann
et al., 2013).
KRAS mutations occur in approximately 20% of non-small-
cell lung cancer (NSCLC) and 40% of colorectal cancer (CRC)
cases, where they are associated with resistance to epidermal
growth factor receptor (EGFR)-targeted therapies (Douillard
et al., 2013; Karapetis et al., 2008; Linardou et al., 2008).
Several strategies have been proposed to target mutant
KRAS tumors. Attempts to inhibit single effectors downstream
to KRAS (e.g., phosphatidylinositol 3-kinase [PI3K] and MEK)
revealed modest or no efficacy (Adjei et al., 2008; Ganesan
et al., 2013). Alternative strategies involve targeting MEK
together with receptor tyrosine kinases including HER3 or insu-
lin-like growth factor 1 receptor (IGF1R) (Ebi et al., 2011; Turke
et al., 2012). Recently, combinatorial treatment with mTOR-tar-
geted agents and BCL-2/BCL-XL inhibitors has also been pro-
posed for KRAS mutant CRCs (Faber et al., 2014). All these
efforts proved to be less broadly applicable than initially
thought, likely due to intrinsic biochemical, biological, and clin-
ical heterogeneity of KRAS mutant tumors, thus explaining why
a specific drug mix may be effective only in a subset of KRAS-
mutated tumors.
Previous studies often employed a limited number of KRAS
mutant tumor cells. The majority of reports frequently relied
upon CRC lines displaying microsatellite instability (MSI). It is
well established that CRCs exhibiting MSI show a particularly
indolent clinical behavior (Roth et al., 2012) and are therefore
less prevalent in more-advanced stages of the disease. Patients
with metastatic CRC (mCRC) that receive targeted agents, such
as anti-EGFR antibodies, showMSI in less than 5% (Smith et al.,
2013). Consequently, MSI cell lines do not properly represent the
clinical setting where KRAS-targeted therapies are likely to be
applied. We sought to overcome these limitations by assembling
and characterizing a broad panel of CRCcell lines carryingKRAS
mutations and lacking MSI.ports 8, 1475–1483, September 11, 2014 ª2014 The Authors 1475
AB
Figure 1. RNAi-Based Suppression of
Genes Involved in KRAS Signaling in a Panel
of CRC Cells Carrying KRAS Mutations
(A) Thirty-seven MSS KRAS-mutated CRC cell
lines were screened with a library of siRNAs de-
signed to target all three isoforms of RAS (KRAS,
HRAS, and NRAS) and their upstream (EGFR,
HER2, HER3, MET, and IGF1R) or downstream
(BRAF, RAF1, PDK1, AKT1, PI3K, MEK1/MEK2,
and ERK1/ERK2) modulators. A pool of four
different siRNAs was used for each gene. After
5 days of treatment, the survival fraction was
determined by ATP assay. Results represent mean
of at least two independent experiments.
(B) Concomitant silencing of two or more effectors
involved in KRAS pathways was assessed. After
5 days of treatment, the survival fraction was
quantified by measuring ATP content. Results
represent mean of at least two independent ex-
periments.
See also Figures S1 and S2.RESULTS
CRC Cell Lines Harboring KRAS-Activating Mutations
Show Differential Sensitivity to Knockdown of Genes
Involved in KRAS Pathways
From an initial collection of 72 CRC KRAS mutant lines, we
selected 39 cell lines with microsatellite stable phenotype
(MSS). SNP genotyping was used to determine the genetic sta-
tus of the entire panel. When multiple cell lines were identified as
being derived from the same individual, only one model was
included in the final panel, which comprised 37 lines (Tables
S1 and S2).
We used a reverse genetics approach to identify genes crit-
ical for the growth of KRAS mutant cancer cells among those
known to be involved in KRAS signaling. To this end, we assem-
bled a library of small interfering RNAs (siRNAs) designed to
target all three isoforms of RAS, their downstream effectors,
and their upstream modulators, such as receptor tyrosine ki-
nases (Figure 1). Each siRNA was individually validated for be-
ing capable of suppressing its target as measured by western
blotting (Figure S1A). A pool of different siRNAs was used for
each gene, and several controls were employed to assess
transfection efficiency and to confirm effective target suppres-
sion (Figures S1B and S2).
When each gene was individually silenced, suppression of
KRAS was by far the most effective, being able to restrain the1476 Cell Reports 8, 1475–1483, September 11, 2014 ª2014 The Authorsgrowth of 25/37 (67%) lines by more than
50% (Figure 1A). Suppression of KRAS
most-immediate effectors such as BRAF,
RAF1, or MEK1+MEK2 was effective in
less than 15% cell lines (Figure 1A). These
results indicate that the occurrence of
mutations generally dictates dependency
on KRAS itself, but not on other single
signaling molecules.
The reverse genetic screen was then
expanded to target two or more genes incombination. Using this strategy, the most effective hit was sup-
pression of MEK1 andMEK2 together with silencing of members
of the RAF family (Figure 1B). Simultaneous downregulation of
MEK1/MEK2, BRAF, and RAF1 reduced cell viability by more
than 50% in a large subgroup of the cells tested (21/37 lines;
57%). This combination was the closest to achieve the same
antiproliferative effects observed with suppression of KRAS
alone (Figure 2A).
A Reverse Genetic Screen Unveils RAF1 Suppression to
Be Synthetic Lethal with MEK Inhibition
A significant fraction of KRAS mutant CRC cells (16/37 lines;
43%) are refractory to MEK-RAF combinatorial suppression.
We postulated that insensitive cell lines might have distinct
signaling features. To gather insights into genes capable of
complementing MEK inhibition in KRAS mutant cells insensi-
tive to RAF suppression, we performed an unbiased screen
using a short hairpin (shRNA) lentiviral library designed to
silence 518 kinase and 17 kinase-related genes. Among the re-
fractory lines, we chose SW480, as this cell line proved
conductive to large-scale lentiviral-based infection. SW480
was infected with the shRNA library and cultured in the pres-
ence or absence of the MEK allosteric inhibitor selumetinib
for 14 days. After this, the relative abundance of shRNA vec-
tors was determined by next generation sequencing of the
bar code identifiers present in each shRNA vector (Figure S3A).
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Figure 2. KRAS Mutant CRC Cell Lines Are
Sensitive to Cosuppression of MEK1/MEK2
and BRAF/RAF1
(A) siRNA-mediated reverse genetic screen
identified cell lines sensitive to combinatorial
suppression of MEK1/MEK2-BRAF-RAF1. Cell
viability was assessed after 5 days of treatment by
measuring ATP content. Data points for each cell
line are expressed as percentage of viability
compared with cells treated with negative control
(AllStar). The horizontal line and error bars indicate
geometric mean ± 95% confidence interval (CI).
(B) Loss-of-function genetic screen nominates
RAF1 suppression as synthetic lethal with MEK
inhibition in SW480 cells. Each shRNA from the
initial screen experiment is represented as a dot in
the plot. The x axis shows the average counts of
sequencing reads in the untreated sample. The y
axis represents the fold change in abundance of
each shRNA in the presence of absence of selu-
metinib.
(C) Suppression of RAF1 or BRAF by shRNA en-
hances response to MEK inhibition. SW480 KRAS
mutant cells were infected with lentiviral shRNAs
targeting RAF1 or BRAF. pLKO.1 empty vector
served as a control vector. After puromycin se-
lection, cells were seeded into 6-well plate (20,000
cells/well) and cultured in the absence or presence
of the MEK inhibitor selumetinib at the indicated
concentration for 2 weeks. At the end of the
experiment, cells were fixed and stained with
crystal violet solution.
(D) Thirty-seven (MSS)KRASmutant cell lineswere
treated with the MEK inhibitor selumetinib, the
pan-RAF inhibitor RAF265, or combination of se-
lumetinib/RAF265 for 5 days. Cell viability was
assessed by measuring ATP content. Data points
are expressed as percent viability compared with
DMSO-only treated cells. The horizontal line and
error bars indicate geometric mean ± 95% CI.
***p < 0.001; **p < 0.01. Cell lines sensitive (LS513
in red) and cell lines insensitive (SW837 in light blue
and SW480 in dark blue) to the combinatorial
treatment are highlighted.
(E) Cells were treated for 5 or 14 days with
increasing concentrations of selumetinib and
RAF265. At the end of the experiment, cells were
fixed and stained with crystal violet solution.
See also Figures S3 and S4.We only considered shRNA vectors that had been sequenced
at least 300 times in the untreated pool. To limit the off-target
effects, hits were selected when two independent shRNAs tar-
geting the same gene were depleted. We rank ordered the
shRNAs by their negative selection in the screen. Using this
criterion, we identified RAF1 as the top gene to have two inde-
pendent shRNAs depleted in the presence of MEK inhibitor
(Figure 2B). Of note, BRAF was also retrieved in this screening.
To validate this—unexpected—finding, we infected SW480Cell Reports 8, 1475–1483, Sepwith two independent RAF1 and BRAF
shRNAs and cultured them with or
without selumetinib for 2 weeks (Figures2C and S3B). The data confirmed results of the large-scale
screening.
RAF-Targeted Agents Synergize with MEK Inhibition in
KRAS Mutant CRC Cells
To extend the findings obtained by transcriptional suppression
of BRAF and RAF1, we performed pharmacological analyses.
RAF1-selective inhibitors are not available. However, several
pan-RAF inhibitors, with different ranges of action on wild-typetember 11, 2014 ª2014 The Authors 1477
RAF1 and wild-type BRAF have been synthesized, although
none has been fully developed for clinical use. For our purposes,
we selected RAF265, a small molecule with inhibitory activity
against wild-type RAF1/BRAF (Su et al., 2012). We treated the
panel of 37 KRASmutant cell lines with RAF265 in the presence
or absence of the MEK inhibitor selumetinib. We found that
concomitant pharmacological inhibition of MEK and RAF led to
a greater than 50% reduction of cell viability in 20/37 (54%)
CRC lines (Figure 2D). To rule out that some of the known off-
target effects of RAF265 (Su et al., 2012) could contribute to
explain its synergy with MEK inhibition, we repeated the cell pro-
liferation assays with AZ628. This compound has been previ-
ously reported to be more selective for wild-type RAF kinases
and has been widely used for in vitro studies (Montagut et al.,
2008; Whittaker et al., 2013). The results obtained with AZ628
in combination with selumetinib are consistent with the observa-
tions made with RAF265 (Figure S4A). Notably, the cells that
were previously identified as sensitive to combined suppression
of RAF1-BRAF and MEK were also affected by the correspond-
ing pharmacological inhibition.
Why are some cells sensitive to inhibition of MEK and RAF in
one experimental condition, but not in the other? We noted
that, whereas siRNA experiments were based on short-term
(5 days) growth assays, the shRNA screening involved a 2-
week-long protocol. We therefore repeated the pharmacological
screening in a long-term assay with two cell models, SW480 and
SW837, which are refractory to the MEK-RAF blockade in the
short-term assays (Figures 2A, 2D, and S4A). Both lines were
treated with RAF265 and selumetinib as single agents, as well
as their combination, for 5 or 14 days (Figure 2E). We found
that the time frame (5 versus 14 days) of the experiments plays
a critical role. Consistent with the reverse genetics screens,
SW480 and SW837 were insensitive in the short-term pharma-
cological assay, whereas after 14 days, both were effectively
inhibited by selumetinib in combination with either RAF265 (Fig-
ure 2E) or AZ628 (Figures S4B and S4C).
MEK Allosteric Inhibition Induces RAF
Heterodimerization and Sustains ERK Activation
The above results point to a critical role for the kinase activity of
BRAF andRAF1 in restraining the effectiveness ofMEK inhibitors
in KRAS-mutated CRC cells. To investigate the biochemical
interplay between RAF suppression and MEK blockade, we per-
formed vertical analysis of the pathway on two cell lines, LS513
and SW480, sensitive to the combinatorial inhibition in short-
term and long-term assay, respectively. As expected, MEK inhi-
bition alone led to increased pMEK and this was accompanied
by incomplete suppression of pERK (Figure 3A). Intriguingly,
MEK blockade also triggered phosphorylation of BRAF at its
serine 445. A modest increase of RAF1 phosphorylation was
also observed. Because KRAS itself is the most well-known acti-
vator of RAF proteins, we measured the activity of KRAS upon
drug treatment. Selumetinib sustained activation of KRAS-GTP
in both LS513 and SW480 cells (Figure 3B) although with a
different magnitude of the effect. We reasoned that MEK inhibi-
tion could initiate a feedback loop involving RAS hyperactivation,
which in turn modulates BRAF and RAF1. To scrutinize further
the impact of RAF activation upon MEK inhibition, we performed1478 Cell Reports 8, 1475–1483, September 11, 2014 ª2014 The Aucoimmunoprecipitation experiments. MEK blockade triggered
the formation of BRAF-RAF1 complexes, which are known to
activate downstream signaling (Figure 3C; Garnett et al., 2005).
Induction of heterodimerization is slightly stronger in SW480
than in LS513, paralleling the magnitude of the effect on RAS-
GTP induction. We propose that, in a KRASmutant background,
MEK inhibition triggers KRAS hyperactivation, leading to
engagement of BRAF/RAF1 heterodimers.
Increased (active) KRAS-GTP levels could result from phos-
phorylation of upstream tyrosine kinase receptors (RTKs), a sce-
nario that has been previously described (Molina-Arcas et al.,
2013; Turke et al., 2012). To confirm this in our cell models, we
performed western blotting to measure levels of phosphorylated
EGFR, HER2, and HER3 proteins upon selumetinib treatment.
MEK blockade induced activation of both EGFR and HER3 in
LS513 (Figure 3D). None of the tested RTKs were significantly
hyperphosphorylated following selumetinib treatment in
SW480 cells. However, in this cell line, we noted a persistent in-
crease of activated AKT1 (Figure 3D), which, in turn, may be
caused by phosphorylation other RTKs, such as IGF1R or
HER3 (Ebi et al., 2011; Sun et al., 2014), or by inhibition of
ERK-dependent feedback loops on AKT (Turke et al., 2012).
Synergistic Inhibition of RAF and MEK Abrogates
ERK Signaling and Triggers Apoptosis in KRAS
Mutant CRC Cells
We next investigated signaling changes induced by concomitant
pharmacological blockade of MEK and RAF in KRAS mutant
CRC cells. Whereas selumetinib as a single agent triggered
MEK and ERK phosphorylation, the addition of RAF265 resulted
in significant reduction of pERK and pAKT levels after 48 hr of
treatment in LS513 cells (Figure 4A). The same effect is not
observed in SW480 cells, which are refractory to concomitant
MEK/RAF blockade in short-term assays (Figure 4B). In line
with this, concomitant inhibition of MEK and BRAF/RAF1 bio-
chemically initiates apoptosis, as confirmed by induction of
PARP cleavage in LS513, but not in SW480 cells. Of note,
MEK—per se—does not lead to PARP activation (Figures 4A
and 4B), thus explaining the striking effects on cell viability
achieved only by RAF/MEK combinatorial blockade.
Combined RAF-MEK Inhibition Shows Synergy in Lung
Cancer Cells Harboring KRAS Mutations
We tested whether combined RAF and MEK inhibition could be
effective also in other cancer types bearing KRAS mutations.
To this end, we repeated the unbiased drop-out shRNA
screening in two KRAS mutant NSCLC cell lines. Notably, as
shown in Figures 5A and 5B, we again retrieved suppression
of RAF1 as being critical to confer sensitivity to MEK inhibition.
The results of the large-scale screening were confirmed by
culturing H358 and H1792 lung cells infected with three inde-
pendent RAF1 or BRAF shRNAs with or without selumetinib
(Figures 5C and 5D). We further find that, as in the CRC setting,
combinatorial pharmacological inhibition of RAF and MEK is
effective in multiple KRAS mutant NSCLC cells (Figures 5E,
5F, S5A, and S5B). In line with this, MEK inhibition induces
BRAF-RAF1 dimerization and concomitant inhibition of MEK
and BRAF/RAF1 initiates apoptosis, as confirmed by inductionthors
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Figure 3. MEK Inhibition Induces KRAS
Activation and RAF Heterodimerization in
KRAS Mutant CRC Cells
(A) Cell lines were treated with selumetinib 0.5 mM
at the indicated time points, after which whole-cell
extracts were subjected to western blot analysis
and probedwith indicated antibodies. Vinculin was
included as a loading control.
(B) Cell lines were treated with selumetinib 0.5 mM
at the indicated time points, after which whole-cell
extracts were subjected to pull-down of active
KRAS-GTP using the GST-RAF1 Ras-binding
domain.
(C) Cell lines were treated with selumetinib 0.5 mM
at the indicated time points, after which whole-cell
extracts were immunoprecipitated with BRAF
antibody and subjected to western blot analysis
with the indicated antibodies. Vinculin was
included as a loading control. Input controls are
shown in (A). IP, immunoprecipitation.
(D) Cell lines were treated with selumetinib 0.5 mM
at the indicated time points, after which whole-cell
extracts were subjected to western blot analysis
and membranes were probed with indicated anti-
bodies. Vinculin was included as a loading control.
See also Figure S5.of PARP cleavage (Figures S5C and S5D). In summary, these
results show that the findings obtained in KRAS-mutated
CRC cells can be extended to lung cancer models bearing
KRAS mutations.
DISCUSSION
Thirty years after their discovery, KRAS-mutated cancers still
pose a formidable challenge to researchers and clinicians alike,
as efforts for direct pharmacological blockade of RAS haveCell Reports 8, 1475–1483, Sepbeen largely unsuccessful. Approxi-
mately 20% of NSCLC and 40% of
CRCs carry somatic variants of the
KRAS gene. Although KRAS mutations
occur at similar frequencies in microsat-
ellite stable and unstable CRCs, the
latter represent a distinct clinical entity.
MSI tumors have a more favorable prog-
nosis and are less prone to lymph node
spread and metastasis than MSS tumors
(Roth et al., 2012). Accordingly, epidemi-
ological analyses indicate that mCRC
patients with KRAS mutant MSS disease
represent the clinical population who
would benefit the most from KRAS
targeting. Based on these premises, we
performed a suppression screen for
genes involved in KRAS signaling in a
collection of 37 MSS KRAS mutant cell
lines. This approach revealed that a
large fraction of CRC cells (67%) were
highly dependent on KRAS expression.
The screening also highlighted thatsilencing of individual genes involved in RAS signaling is inef-
fective on suppressing the growth of KRAS mutant CRC cells.
This suggests that RAS controls a largely redundant signaling
network, which guarantees that interference with an individual
effector does not interrupt pathway output (Cox and Der, 2010;
Gysin et al., 2011). The architecture of the EGFR-RAS-MEK-
signaling pathway is evolutionarily ancient and increased in
complexity during evolution (Malumbres and Barbacid, 2003;
Yarden and Pines, 2012). In vertebrate cells, this signaling
network allegedly encompasses several interconnected routes.tember 11, 2014 ª2014 The Authors 1479
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Figure 4. Concomitant Inhibition of MEK and RAF Induce Apoptosis
in KRAS Mutant CRC Cells
LS513 (A) and SW480 (B) cells were treated with increasing concentrations of
selumetinib or selumetinib combined with different concentration of RAF265
for 48 hr. Lysates were subjected to western blot analyses, and membranes
were probed with the indicated antibodies. Vinculin was included as a loading
control. See also Figure S5.To identify signaling nodes in the EGFR-KRAS-MEK network
whose concomitant blockade might suppress the growth of
KRAS mutant cells, we performed a combinatorial siRNA
screen. The results showed that suppressing MEK is almost
invariably necessary but nearly always insufficient to halt
growth of KRAS-mutated cells. Genes retrieved as being
capable of synergizing with MEK silencing could be cataloged
in two classes: members of the receptor tyrosine kinase family
(RTKs) and elements of the RAF family of serine/threonine ki-
nases. Blockade of RTKs (such as EGFR, HER3, IGF1R, and
MET) in conjunction with MEK inhibition for KRAS mutant1480 Cell Reports 8, 1475–1483, September 11, 2014 ª2014 The AuCRCs has been explored in several previous studies (Ebi
et al., 2011; Molina-Arcas et al., 2013; Sun et al., 2014; Turke
et al., 2012; Van Schaeybroeck et al., 2014). In this work, we
focused instead on co-targeting RAFs and MEK. We found
that this combination is effective in 21/37 (57%) of KRAS
mutant MSS CRC cell lines. To understand why the combina-
tion was ineffective in a significant proportion of the cell
models, one of the refractory lines was subjected to an unbi-
ased drop-out screen to unveil kinase genes synergizing with
MEK inhibition. Rather unexpectedly, these experiments
retrieved again RAF1. Importantly, the same synergistic inter-
action was confirmed, by shRNA screening, in two NSCLC
cell lines bearing KRAS mutations. This incongruity was
resolved when combined RAF-MEK suppression was tested
in short- and long-term assays and showed to be active in a
large proportion of mutant KRAS CRC and NSCLC cell lines
when both conditions were examined. Why should suppression
of RAF, which acts immediately upstream of MEK, be neces-
sary to halt growth of KRAS mutant CRCs? We found that
MEK inhibition increases the GTP-bound fraction of KRAS,
promotes the formation of RAF1-BRAF heterodimers (the
most active complex among all RAF dimers), and drives consti-
tutive phosphorylation of ERK. These results are in accordance
with a recent report showing that RAF1 knockdown enhanced
MEK inhibition in a KRAS mutant model (Lito et al., 2014). Lito
et al. (2014) found that allosteric inhibitors of MEK, such as se-
lumetinib, can induce the formation of RAF-MEK complexes in
KRAS mutant cells. This effect may be less relevant or not pre-
sent with new-generation catalytic MEK inhibitors, but addi-
tional studies are needed to assess the activity of these
MEK-targeted agents in the context of mutant KRAS.
Among the additional hits retrieved by our screen, co-
silencing of ERK1 and ERK2 reduced the viability by less than
50% in 15/37 KRAS mutant CRC cell lines. ERK inhibitors are
still in preclinical development, and their efficacy in KRAS
mutant cancers has not been extensively investigated. How-
ever, previous works suggest that blockade of the EGFR-
RAS-MEK axis with agents targeting a single node has often
limited impact due to feedback reactivation of the signaling
pathway (Ebi et al., 2011; Molina-Arcas et al., 2013; Sun et al.,
2014; Turke et al., 2012; Van Schaeybroeck et al., 2014). Of
relevance, it has recently been reported that BRAF mutant mel-
anoma cells are often resistant to ERK inhibition, because the
relief of ERK-dependent negative feedback can activate RAS
and PI3K signaling (Carlino et al., 2014). Nevertheless, our
data suggest that future studies are needed to investigate the
biological effects of ERK inhibition and its biochemical conse-
quences within the context of mutant KRAS.
We propose a model whereby KRAS mutant cancers can be
besieged with two, non-mutually exclusive approaches. The first
involves blockade of the upstream RTKs, which presumably are
activated through one of the feedback loops that we and others
had previously identified (Ebi et al., 2011; Misale et al., 2014;
Molina-Arcas et al., 2013; Prahallad et al., 2012; Sun et al.,
2014; Turke et al., 2012). For this strategy to be successful, a pri-
ori knowledge of the RTK involved in a given tumor/patient is
essential or the use of inhibitors capable of intercepting simulta-
neously multiple RTKs must be applied. This approach isthors
Figure 5. RAF1 Is Synthetic Lethal with MEK
Inhibition in KRAS Mutant NSCLC Tumors
(A and B) Loss-of-function genetic screen retrieves
RAF1 suppression as synthetic lethal with MEK in-
hibition in H358 (A) and H1792 (B) NSCLC cells.
Each shRNA from the initial screen experiment is
represented as a dot in the plot. The x axis shows
the average counts of sequencing reads in the un-
treated sample. The y axis represents the fold
change in abundance of each shRNA in the pres-
ence or absence of selumetinib.
(C and D) Suppression of RAF1 or BRAF by shRNA
enhances response to MEK inhibition. H358 (A) and
H1792 (B) KRAS mutant cells were infected with
lentiviral shRNAs targeting RAF1 or BRAF. pLKO.1
empty vector served as a control vector. After pu-
romycin selection, cells were seeded into 6-well
plate (20,000 cells/well) and cultured in the absence
or presence of the MEK inhibitor selumetinib at the
indicated concentration for 2 weeks. At the end of
the experiment, cells were fixed and stained with
crystal violet solution. The level of RAF1 and BRAF
knockdownwas determined bywestern blot. ERK1/
ERK2 served as a loading control.
(E and F) NSCLC cells were treated 14 days with
increasing concentrations of selumetinib and
AZ628. At the end of the experiment, cells were
fixed and stained with crystal violet solution.
See also Figure S5.hindered by the need for biomarkers to reliably assess the feed-
back loop engaged in each individual tumor; the second strat-
egy is likely associated with toxicity and limited therapeutic in-
dex, which often accompany multikinase inhibitors.
An alternative approach, which we have outlined in this work,
involves interfering with mutant KRAS by concomitant blockade
of MEK and RAFs. The exploitation of this tactic depends on the
development of a new class of—clinically suited—inhibitors
capable of simultaneously blocking wild-type BRAF and RAF1.
Tool compounds having this activity are available mainly for
in vitro use, but these compounds are highly toxic, even to exper-Cell Reports 8, 1475–1483, Seimental animals. Thus, further testing
in vivo of the combination therapy pro-
posed here will require the development
of a new generation of pan-RAF inhibitors
with better pharmacological properties.
EXPERIMENTAL PROCEDURES
Cell Lines
The cell lines used in this study were collected
from commercial sources or academic laboratories
as indicated in Table S1. Cells were kept in the
indicated culture growth media supplemented
with 10% FBS, 50 units/ml penicillin, 50 mg/ml
streptomycin, and 0.25 mg/ml Fungizone. The ge-
netic identity of each cell line was confirmed by
short tandem repeat profiling (Cell ID System;
Promega), and the cells were last checked no
less than 3 months before performing reverse ge-
netics screen experiments. Results of the analyzed
loci for each cell line are provided in Table S2. AllCRC cell lines were maintained in a humidified atmosphere of 95% air and
5% CO2 at 37C.
siRNA Screening
The siRNA-targeting reagents were purchased from Dharmacon, as a
SMARTpool of four distinct siRNA species targeting different sequences of
the target transcript. Cell lines were grown and transfected with SMARTpool
siRNAs using Dharmafect 4 (Dharmacon), Lipofectamine2000, or RNAiMAX
(Invitrogen) transfection reagents following manufacturer’s instructions.
Briefly RNAi screening conditions were as follows: on day 1, siRNA were
distributed in each well of a 384-wells plate at final concentration of
20 nmol/l. Transfection reagents were incubated in OptiMEM serum-freeptember 11, 2014 ª2014 The Authors 1481
media for 20 min and aliquoted at 10 ml/well; after that, 35 ml of cells in media
without antibiotics were added to each well. After 5 days, cell viability was
estimated with a luminescent assay measuring cellular ATP levels (CellTiter-
Glo Luminescent Assay; Promega). Each plate included the following con-
trols: mock control (transfection lipid only), siControl1 (Dharmacon), AllStars
(QIAGEN) as negative control, and polo-like kinase 1 (Dharmacon), which
served as positive control (Brough et al., 2011). The RNAi screens were car-
ried out in quadruplicate, and survival fraction was calculated as a ratio
between the average of experiment well readout and the negative control,
nontargeting siRNA (AllStars; QIAGEN).
Loss-of-Function shRNA Screen
The shRNA library used in this study was designed to target 535 human ki-
nases and kinase-related genes. The lentiviral-based vectors were collected
from The RNAi Consortium (TRC) human genome-wide shRNA collection
(TRC-Hs1.0). SW480 cells were infected by pooled lentivirus generated from
the above-mentioned shRNA library. After puromycin selection, cells were
cultured in the presence or absence of selumetinib. shRNA sequences were
recovered by PCR, and the abundance of each hairpin in pooled samples
was determined by deep sequencing.
Drug Proliferation Assay
CRC cell lines were seeded at different densities (1.5–2.5 3 103cells/well) in
100 ml complete growth medium in 96-well plastic culture plates at day 0.
The following day, serial dilutions of selumetinib and RAF265 were added to
the cells in serum-free medium, whereas DMSO-only treated cells were
included as controls. Plates were incubated at 37C in 5%CO2 for 5 days, after
which, cell viability was assessed by measuring ATP content through Cell
Titer-Glo Luminescent Cell Viability assay (Promega). For long-term prolifera-
tion assays, cells were seeded in 24-well plates (3–5 3 103 cells per well) and
cultured in the absence and presence of drugs as indicated. Wells were fixed
with 3% paraformaldehyde and stained with 1% crystal violet-methanol solu-
tion (Sigma-Aldrich) after 2 weeks. All assays were performed independently at
least three times. AZ628, selumetinib, and RAF265 were purchased from Sell-
eck Chemicals.
Western Blotting Analysis and Immunoprecipitation
Prior to biochemical analysis, all cells were grown in their specific media sup-
plemented with 10% FBS and treated with selumetinib or RAF265 at indicated
time points and concentrations. Total cellular proteins were extracted by sol-
ubilizing the cells in boiling SDS buffer (50mMTris-HCl [pH 7.5], 150mMNaCl,
and 1% SDS) or in cold extraction buffer (50 mM HEPES [pH 7.4], 150 mM
NaCl, 1% Triton X-100, 10% glycerol, 5 mM EDTA, and 2 mM EGTA; all re-
agents were from Sigma-Aldrich, except for Triton X-100 from Fluka) in the
presence of 1 mM sodium orthovanadate, 100 mM sodium fluoride, and a
mixture of protease inhibitors (pepstatin, leupeptin, aprotinin, soybean trypsin
inhibitor, and phenylmethylsulfonyl fluoride). Extracts were clarified by centri-
fugation, and protein concentration was determined using BCA Protein Assay
Reagent kit (Thermo Scientific). Western blot detection was performed with
enhanced chemiluminescence system (GE Healthcare) and peroxidase conju-
gated secondary antibodies (Amersham). The following primary antibodies
were used for western blotting (all from Cell Signaling Technology, except
where indicated): anti-phospho- BRAF (Ser445); anti-BRAF (Santa Cruz);
anti-phospho-RAF1 (Ser338); anti RAF1; anti-phospho-p44/42 ERK (Thr202/
Tyr204); anti-p44/42 ERK; anti-phospho-MEK1/MEK2 (Ser217/Ser221), anti-
MEK1/MEK2; anti-KRAS (Sigma Aldrich); anti-EGFR (clone13G8; Enzo Life
Sciences); anti-phospho AKT (Ser473); anti-AKT; anti-phospho EGFR
(Tyr1068; Abcam); anti-phospho-HER2 (Tyr1221/Tyr1222); anti-HER2 (Santa
Cruz); anti-phosphor-HER3 (Tyr 1289); anti-HER3 (Millipore); antivinculin (Milli-
pore); and antiactin (Santa Cruz). Immunoprecipitation was carried out
following cell lysis in extraction buffer in the presence of 1 mM sodium ortho-
vanadate, 100 mM sodium fluoride, and protease and phosphatase inhibitors.
Extracts were clarified by centrifugation, normalized with the BCA Protein
Assay Reagent kit (Thermo Scientific), and incubatedwith indicated antibodies
for 2 hr at 4C. Immune complexes were collected with protein A-Sepharose,
washed in extraction buffer, and eluted. Extracts were electrophoresed on
SDS-polyacrylamide gels and processed as described before.1482 Cell Reports 8, 1475–1483, September 11, 2014 ª2014 The AuRAS Activation Assay
GST-RAF1-RAS-binding domain fusion proteins were expressed in Escheri-
chia coli by induction with 0.2 mM isopropyl-1-thiob-D-galactopyranoside
for 4 hr at 30C. The expressed fusion proteins were isolated from bacterial ly-
sates by affinity chromatography with glutathione agarose beads. Six hundred
micrograms of whole-cell cleared lysate was incubated with 10 mg of GST-
RAF1-Ras-binding domain for 90 min at 4C. The complexes were collected
by centrifugation andwashed three timeswith lysis buffer. Proteins were sepa-
rated by SDS-PAGE followed by western blot. The KRAS protein was detected
with anti-KRAS monoclonal antibody (Sigma-Aldrich). Total lysates (20 mg)
from the above cells were immunoblotted with anti-KRAS antibody (Sigma-
Aldrich) as a loading control.
Statistical Analysis
Statistical significance for the data of the short-term drug assays was deter-
mined by nonparametric Kruskal-Wallis statistics with a Dunn’s multiple com-
parison posttest. This test was chosen because the data did not follow a
normal distribution. p < 0.01 and p < 0.001 were considered statistically
significant.
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